

CITATION REPORT

List of articles citing

Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial

DOI: 10.1111/dom.14392

Diabetes, Obesity and Metabolism, 2021, 23, 1786-1794.

Source: <https://exaly.com/paper-pdf/80665785/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1786-1794	6.7	4
4	Immunogenicity of LY2963016 insulin glargine and Lantus [®] insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	0
3	Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial. <i>Diabetes Therapy</i> , 2021 , 13, 161	3.6	
2	Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type ¹ Diabetes Previously Treated with Insulin Glargine (Lantus): a Post Hoc Analysis of a Randomized, Open-Label, Phase ³ Trial.. <i>Diabetes Therapy</i> , 2022 , 1	3.6	0
1	New Insulins, Biosimilars, and Insulin Therapy.. <i>Diabetes Technology and Therapeutics</i> , 2022 , 24, S35-S57	8.1	